Epigenetic Manipulation of the Somatostatin Receptor Type 2 in Neuroendocrine Tumor Cells

#1097

Introduction: The somatostatin receptor type 2 (sst2) is a target for treatment in patients with neuroendocrine tumors (NET). However, variability in tumoral sst2 expression might lead to variability in response. Epidrugs could increase sst2 levels and improve response to somatostatin analogues (SSA).

Aim(s): Determine the effect of the DNA demethylating drug 5-aza-2’-deoxycytidine (5-aza-dC) and histone deacetylase inhibitor Valproic Acid (VPA) on sst2 mRNA, internalization and cAMP signaling in NET cell lines BON and QGP.

Materials and methods: After 7 days treatment with 5-aza-dC, VPA or both, sst2 mRNA values were determined by Q-RT-PCR, as well as the effect on uptake of [125I-Tyr3]octreotide and in BON on the inhibition of forskolin-stimulated cAMP expression by octreotide.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Veenstra M, Van Koetsveld P, Dogan F, Farrell W, Vitale G,

Keywords: NET, sst2, epidrug, signaling,